Company Filing History:
2 out of 3 
2 out of 1,743 
2 out of 170 
Years Active: 2020-2021
Title: Eric Robinet: Innovator in Hepatocellular Carcinoma Research
Introduction
Eric Robinet is a notable inventor based in Colmar, France. He has made significant contributions to the field of medical research, particularly in the area of hepatocellular carcinoma. With a total of 2 patents, his work focuses on innovative treatments for liver diseases.
Latest Patents
Robinet's latest patents include the development of anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma. These patents describe the use of these antibodies and pharmaceutical compositions for patients suffering from liver disease, especially those not associated with HCV infection or those who have been cured from HCV infection. The methods outlined in his patents detail the administration of these monoclonal antibodies and provide experimental results using the hepatocarcinoma cell line HuH-7.5.1.
Career Highlights
Throughout his career, Eric Robinet has worked with prestigious institutions such as the Institut Hospitalier Universitaire de Strasbourg and the Institut National de la Santé et de la Recherche Médicale. His research has been pivotal in advancing the understanding and treatment of liver diseases.
Collaborations
Robinet has collaborated with esteemed colleagues, including Thomas Baumert and Mirjam Zeisel, contributing to the collective effort in hepatocellular carcinoma research.
Conclusion
Eric Robinet's innovative work in the field of hepatocellular carcinoma showcases his dedication to improving treatment options for patients. His contributions through patents and collaborations highlight the importance of research in advancing medical science.